Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
0.906
+0.012 (1.33%)
At close: Nov 22, 2024, 4:00 PM
0.890
-0.015 (-1.71%)
After-hours: Nov 22, 2024, 7:54 PM EST
Tempest Therapeutics Employees
Tempest Therapeutics had 17 employees as of December 31, 2023. The number of employees decreased by 2 or -10.53% compared to the previous year.
Employees
17
Change (1Y)
-2
Growth (1Y)
-10.53%
Revenue / Employee
n/a
Profits / Employee
-$2,089,294
Market Cap
24.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | 17 | 3 | 21.43% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| DarioHealth | 294 |
| Athira Pharma | 67 |
| HCW Biologics | 45 |
| Femasys | 34 |
| Pulmatrix | 22 |
| NEXGEL | 19 |
| iBio, Inc. | 16 |
TPST News
- 10 days ago - Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? - Benzinga
- 6 weeks ago - Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial - GlobeNewsWire
- 2 months ago - Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma - GlobeNewsWire
- 3 months ago - Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire